Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Therapy

Pulmonx Corp stock (ISIN: US74586W1018) has shed 76% year-to-date, trading near $1.64, yet analysts project 367% upside to $7.66, driven by strong revenue beats and expanding emphysema treatment adoption in Europe.

Pulmonx Corp stock (ISIN: US74586W1018), listed on NASDAQ as LUNG, has plunged 75.8% since the start of 2025, closing recently at around $1.64 amid broader small-cap medtech pressures. The company, a leader in bronchoscopic lung volume reduction for severe emphysema patients, beat Q3 2025 revenue estimates with $23.86 million, signaling resilient demand for its Zephyr Valve system despite negative margins. For European investors, particularly in DACH markets with high COPD prevalence, this setup offers a high-conviction growth play if execution holds.

As of: 15.03.2026

By Dr. Elena Voss, Senior Medtech Analyst with focus on respiratory innovations and European market access.

Current Market Situation for Pulmonx Shares

The **Pulmonx Corp stock (ISIN: US74586W1018)** now commands a market cap of roughly $67 million, with shares oscillating between a 52-week low of $1.47 and high of $9.37. Trading volume averages 253,502 shares daily, recently spiking amid volatility. Short interest stands at a moderate 3.53%, down 19.10% month-over-month, hinting at improving sentiment as bears cover positions.

Analyst consensus remains 'Hold' with a 2.40 rating score from 10 reports: 5 Buys, 4 Holds, 1 Sell. Price targets cluster around $7.66, implying 367% upside from current levels, or conservatively $5.38 for 220% potential. This divergence underscores why risk-tolerant DACH investors track it via Xetra, where euro-denominated liquidity aids USD hedging.

P/B ratio at 0.76 suggests asset undervaluation relative to book value, atypical for loss-making growth medtech but appealing for value hunters. No dividend yield exists, as cash fuels R&D and sales expansion.

Recent Earnings Beat and Operational Momentum

In its last reported quarter (Q3 2025, announced July 30), Pulmonx posted $23.86 million revenue, topping expectations of $23.46 million by 0.4 million. EPS came in at -$0.38, better than the -$0.40 forecast, though trailing twelve-month net margins linger at -62.88% due to scaling investments. Return on equity is negative at -69.76%, standard for pre-profit medtech firms prioritizing market share.

Core driver: the Zephyr Endobronchial Valve system, which targets hyperinflated lung segments in emphysema patients via minimally invasive bronchoscopy. Installed base expansion accelerates as more centers adopt it, boosting consumables pull-through - a classic medtech model where upfront procedure kits drive recurring revenue from valves and accessories. Projections eye EPS improvement from -$1.55 to -$1.38 next year, assuming 20%+ revenue growth.

Why now? Emphysema affects millions globally, with Europe facing acute demand from aging populations and historical smoking rates. DACH regions report high COPD incidence - Germany alone sees 10% adult prevalence - positioning Pulmonx for CE Mark leverage and local partnerships.

Margins, Cost Structure, and Path to Leverage

Gross margins hover near 60%, powered by high-margin consumables that form the bulk of revenue post-initial system sales. Operating losses stem from elevated R&D (new indications like heterogeneous emphysema) and global sales force buildout. Fixed costs dilute per-unit economics now, but scale promises leverage: as procedures grow, margins could expand 5-10 points annually.

Compared to diagnostics/life sciences peers, Pulmonx's model mirrors consumables-heavy plays where installed base dictates longevity. Break-even targets circa 2028 hinge on procedure volumes doubling via reimbursement wins. European angle: EMA approvals and HTA bodies in Germany (IQWiG) could fast-track adoption, reducing U.S.-centric risks for DACH portfolios.

Cash burn remains controlled, with revenue outpacing expense growth. Negative ROE reflects reinvestment, not distress - a trade-off growth investors accept for 20-30% CAGR potential.

Balance Sheet Strength and Capital Allocation

Pulmonx maintains a clean balance sheet with sufficient liquidity for 2-3 years runway, absent major debt. Capital deploys primarily to R&D (20-25% of revenue) and sales/marketing (40%+), forgoing buybacks or dividends. This growth focus suits medtech at this stage, akin to CVRx or other device innovators.

No dilution pressure imminent, though equity raises remain a watch item in volatile markets. Free cash flow turns positive post-profitability, potentially unlocking returns. For Swiss investors eyeing franc stability, Pulmonx's U.S. dollar exposure warrants currency overlays, but Xetra trading mitigates timing issues.

Technical Setup, Sentiment Shift, and Analyst Views

Charts show shares testing $1.47 support, with RSI in oversold territory signaling rebound potential. Volume upticks on green days suggest accumulation. Sentiment brightens via short covering, contrasting 2025's downtrend.

Analysts' 367% upside bets on procedure growth and margin inflection. 'Hold' consensus tempers enthusiasm, reflecting execution risks, but Buy ratings from sector specialists highlight conviction. DACH traders benefit from extended hours alignment via European exchanges.

Sector Context: Respiratory Medtech Demand Surge

Pulmonx operates in a niche but expanding bronchoscopic space, where emphysema therapies shift from surgery to outpatient procedures. Competitors lag in valve efficacy data, giving Zephyr a moat via FDA Breakthrough status and real-world evidence. Global COPD market exceeds $20 billion, with minimally invasive segment growing 15% CAGR.

Europe drives relevance: high reimbursement in Germany/France contrasts U.S. payer fragmentation. DACH investors favor such profiles, blending biotech upside with device predictability - think Straumann in dentals, but for lungs.

Catalysts Ahead: Earnings, Data, and Expansion

Key triggers: Q1 2026 earnings (EPS est. -$0.33), European procedure data, potential partnerships. FDA expansions or HTA nods could catalyze 50%+ moves. Revenue >20% YoY sustains runway, targeting 100k+ annual procedures long-term.

Austria/Switzerland's precision medicine ethos aligns with Pulmonx's data-driven approach, possibly spurring local trials.

Risks and Trade-Offs for Investors

Primary risks: slow clinician adoption, reimbursement hurdles, competition from pharma alternatives. Macro headwinds hit small caps hard, amplifying volatility. Dilution or trial setbacks could pressure shares further.

Trade-off: high beta (3x market) suits tactical plays, not core holdings. DACH perspective: COPD burden justifies monitoring, but pair with diversified medtech exposure.

Outlook: Break-Even Path and Investor Implications

If trends hold, Pulmonx nears profitability inflection, rewarding patient capital with multi-baggers. European traction accelerates this, making it a watchlist staple for growth-oriented portfolios. Monitor Q1 for confirmation.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.